Breast Cancer

Providers need to better inform patients about the risks of heart disease compared with breast cancer.

Patients who underwent surgery and then standard treatment lived 9 months longer than patients who just had the standard treatment.

Recent advances and updates in oncology and cancer drug development.

Patients who underwent surgery and then standard treatment lived 9 months longer than patients who just had the standard treatment.

Providers need to better inform patients about the risks of obesity and heart disease compared with breast cancer.

Breast cancer treatments that are similar in effectiveness are priced very differently, researchers discovered.

Combination imaging found to reduce recall rate in patients with breast cancer.

Informed choices of therapy regimens could save up to $1 billion annually in cancer drug spending.

Metformin found to improve survival in breast cancer and shows promise in endometrial hyperplasia.

Top news of the day from across the health care landscape.

Risk of developing breast cancer in women with a BRCA1 mutation may be reduced.

Women diagnosed with breast cancer who carry a BRCA mutation have up to a 50% lifetime risk of developing a second breast cancer.

Postmenopausal women with early breast cancer showed a reduction in disease recurrence after 10 years of aromatase inhibitor therapy with letrozole.

Biosimilar trastuzumab antibody (MYL-1401O) comparable in efficacy and safety to targeted cancer drug in women with HER2-positive advanced breast cancer.

Alcohol found to affect biologic mechanisms that raise the risk of cancer.

Improved cancer detection rates and a reduced recall rates can be enhanced.

Anthracycline chemotherapy for breast cancer treatment may not cause decline in cognitive function.

The PI3K/AKT pathway may provide a new therapeutic target for breast cancer combination therapy.

Treatment approach may eradicate triple-negative breast cancer.

Cancer diagnosis may potentially cause a decrease in physical function and mental health.

Cisplatin kills both rapidly dividing cells and non-dividing cells in the inner ear, which can lead to hearing loss.

Epigenetic changes can leave cancer stem cells vulnerable to a combination of 5-azacytidine and butyrate.

Targaprimir-96 causes programmed cell death in breast cancer animal models.

Top news of the day from across the health care landscape.

Blocking estrogen production by using an aromatase inhibitor stopped seizures in animal models.